Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in
recurrent and/or aggressive meningiomas growth with limited adverse effects.